Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Biomarkers, Treatments, and Clinical Outcomes for Meningiomas and Other Skull...
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Biomarkers, Treatments, and Clinical Outcomes for Meningiomas and Other Skull Base Tumors

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 August 2025 | Viewed by 5635

Special Issue Editors

Prof. Dr. Michael Graner

E-Mail Website
Guest Editor
Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Interests: menigioma and skull base tumor genetics; exosomes; biomarker discovery; drug screening
Dr. Philip David Tatman

E-Mail Website
Guest Editor
Department of Neurosurgery, University of Colorado, Aurora, CO, USA
Interests: menigioma and skullbase tumor genetics; genomic structural variants; biomarker discovery; drug screening

Special Issue Information

Dear Colleagues,

Skull base tumors such as meningiomas can prove challenging to diagnose and treat, with accompanying physical and socioeconomic deficits, other morbidities, and even mortality. These tumors are also understudied compared to other cancers, highlighting a need for more research. This Special Issue on the Biomarkers, Treatment, and Clinical Outcomes for Meningiomas and Skull Base Tumors is intended to highlight excellent molecular mechanism and pathophysiology research focused on (1) biomarker discovery and clinical variables associated with prognostic outcomes of meningiomas and other skull base tumors, as well as (2) identifying potential surgical, radiologic, pharmacologic, or other interventions, treatments, and treatment targets for these tumors. We welcome expert opinions, reviews, original basic science research, and all publications that focus on the molecular mechanisms or pathophysiology of skull base tumors, with the goal of progressing our understanding and the treatment of these tumors. Clinical trials and data without a basis in molecular mechanisms are discouraged from this special edition.

Prof. Dr. Michael Graner
Dr. Philip David Tatman
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skull base tumor
  • meningioma
  • biomarkers
  • diagnosis
  • prognosis
  • radiology
  • surgery
  • pharmacotherapy
  • immunology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

25 pages, 7668 KiB  
Article
Extracellular Vesicles from a Novel Chordoma Cell Line, ARF-8, Promote Tumorigenic Microenvironmental Changes When Incubated with the Parental Cells and with Human Osteoblasts
by Khoa N. Nguyen, Arin N. Graner, Anthony R. Fringuello, Zoe Zizzo, Lorena Valenzuela, Kamara Anyanwu, Kevin O. Lillehei, A. Samy Youssef, Samuel Guzman, Christina Coughlan and Michael W. Graner
Int. J. Mol. Sci. 2024, 25(23), 12731; https://doi.org/10.3390/ijms252312731 - 27 Nov 2024
Viewed by 1270
Abstract
Chordomas are rare, generally slow-growing spinal tumors that nonetheless exhibit progressive characteristics over time, leading to malignant phenotypes and high recurrence rates, despite maximal therapeutic interventions. The tumors are notoriously resistant to therapies and are often located in regions that complicate achieving gross [...] Read more.
Chordomas are rare, generally slow-growing spinal tumors that nonetheless exhibit progressive characteristics over time, leading to malignant phenotypes and high recurrence rates, despite maximal therapeutic interventions. The tumors are notoriously resistant to therapies and are often located in regions that complicate achieving gross total resections. Cell lines from these tumors are rare as well. We cultured a new chordoma cell line (ARF-8) derived from an extensive clival chordoma that extended back to the cervical spine. We characterized the ARF-8 cellular and extracellular vesicle (EV) proteomes, as well as the impacts of ARF-8 EVs on the proteomes and secretomes of recipient cells (both ARF-8 and human osteoblasts) in autocrine and paracrine settings. Our proteomic analyses suggested roles for transforming growth factor beta (TGFB/TGFβ), cell–matrix interactions involving the epithelial-to-mesenchymal transition (EMT), and cell–extracellular matrix interactions in cell migration, consistent with a migratory/metastatic tumor phenotype. We demonstrated that ARF-8 tumor cell migration was dependent on general (arginine–glycine–aspartic acid [RGD]-based) integrin activity and that ARF-8 EVs could promote such migration. ARF-8 EVs also prompted proteomic/secretomic changes in human osteoblast cells, again with indications that cell–cell and cell–extracellular matrix interactions would be activated. All the characteristics typically associated with chordomas as cancers—migration and invasion, therapeutic resistance, metastatic potential—can be driven by tumor EVs. Overall, ARF-8 EVs promoted predicted tumorigenic phenotypes in recipient cells and suggested novel therapeutic targets for chordomas. Full article
(This article belongs to the Special Issue Biomarkers, Treatments, and Clinical Outcomes for Meningiomas and Other Skull Base Tumors)
►▼ Show Figures

Graphical abstract

19 pages, 5084 KiB  
Article
Effect of Different Glucose Levels and Glycation on Meningioma Cell Migration and Invasion
by Philipp Selke, Christian Strauss, Rüdiger Horstkorte and Maximilian Scheer
Int. J. Mol. Sci. 2024, 25(18), 10075; https://doi.org/10.3390/ijms251810075 - 19 Sep 2024
Viewed by 1367
Abstract
Meningiomas are predominantly benign tumors, but there are also malignant forms that are associated with a poor prognosis. Like almost all tumors, meningiomas metabolize glucose as part of aerobic glycolysis (Warburg effect) for energy supply, so there are attempts to influence the prognosis [...] Read more.
Meningiomas are predominantly benign tumors, but there are also malignant forms that are associated with a poor prognosis. Like almost all tumors, meningiomas metabolize glucose as part of aerobic glycolysis (Warburg effect) for energy supply, so there are attempts to influence the prognosis of tumor diseases using a glucose-reduced diet. This altered metabolism leads to so called hallmarks of cancer, such as glycation and glycosylation. In this study, we investigated the influence of low (3 mM), normal (5.5 mM) and high glucose (15 mM) on a malignant meningioma cell line (IOMM-Lee, WHO grade 3). In addition, the influence of methylglyoxal, a by-product of glycolysis and a precursor for glycation, was investigated. Impedance-based methods (ECIS and RTCA) were used to study migration and invasion, and immunoblotting was used to analyze the expression of proteins relevant to these processes, such as focal adhesion kinase (FAK), merlin or integrin ß1. We were able to show that low glucose reduced the invasive potential of the cells, which was associated with a reduced amount of sialic acid. Under high glucose, barrier function was impaired and adhesion decreased, which correlated with a decreased expression of FAK. Full article
(This article belongs to the Special Issue Biomarkers, Treatments, and Clinical Outcomes for Meningiomas and Other Skull Base Tumors)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 506 KiB  
Review
The Molecular and Immunological Landscape of Meningiomas
by Catharina Lotsch, Rolf Warta and Christel Herold-Mende
Int. J. Mol. Sci. 2024, 25(17), 9631; https://doi.org/10.3390/ijms25179631 - 5 Sep 2024
Cited by 2 | Viewed by 2351
Abstract
Meningiomas are the most common primary intracranial tumors in adults and typically have a slow-growing and benign nature. However, there is also a substantial subset of meningiomas that shows aggressive clinical behavior and is refractory to standard treatment modalities, which are still limited [...] Read more.
Meningiomas are the most common primary intracranial tumors in adults and typically have a slow-growing and benign nature. However, there is also a substantial subset of meningiomas that shows aggressive clinical behavior and is refractory to standard treatment modalities, which are still limited to surgery and/or radiotherapy. Despite intensive research, no systemic treatment options are yet available in the clinic for these challenging tumors, resulting in poor patient outcome. Intensive research on the molecular pathogenesis of meningiomas has led to improved diagnostic tools, but so far there is no standardized implementation for the molecular profiling of these tumors for clinical practice. Recent research advances have also focused on the immunophenotyping of meningiomas, leading to several clinical trials examining the use of immune checkpoint blockade therapy in patients with clinically aggressive subtypes. In this review, we aim to summarize the current knowledge on the molecular and immunological landscape of meningiomas in detail and provide current and progressive ideas for future directions. Full article
(This article belongs to the Special Issue Biomarkers, Treatments, and Clinical Outcomes for Meningiomas and Other Skull Base Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop